OncoMatch/Clinical Trials/NCT06420063
Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML
Is NCT06420063 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies CD123/CD33 CART for aml.
Treatment: CD123/CD33 CART — This is an open, single-arm, clinical study to evaluate the efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) targeting CD33 or CD123 or both sequentially in the treatment of Acute Myelocytic Leukemia.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: CLEC12A overexpression
Confirmed expression of CLL-1, CD123 and/or CD33 in blast AML by immuno-histochemical staining or flow cytometry
Required: IL3RA overexpression
Confirmed expression of CLL-1, CD123 and/or CD33 in blast AML by immuno-histochemical staining or flow cytometry
Required: CD33 overexpression
Confirmed expression of CLL-1, CD123 and/or CD33 in blast AML by immuno-histochemical staining or flow cytometry
Lab requirements
Blood counts
hgb≥80g/l
Kidney function
creatinine ≤ 2.5 × upper limit of normal
Liver function
ast and alt ≤ 3 × upper limit of normal, total bilirubin ≤ 2.0mg/dl
Cardiac function
cardiac ejection fraction ≥ 50%, oxygen saturation ≥ 90%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify